Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pre-emption: Obama Administration Creeps Towards Reversing FDA Stance

Executive Summary

FDA has not yet altered its support of pre-emption in product liability suits but there are signs it may do so under the Obama administration

You may also be interested in...



Vaccine Liability Question Is Urgent, Gov't. Says; Supreme Court Takes Up Case

At the encouragement of the government, the U.S. Supreme Court agreed to take up the question of whether a federal law shields vaccine manufacturers from all liability for alleged vaccine design defects

Vaccine Liability Question Is Urgent, Gov't. Says; Supreme Court Takes Up Case

At the encouragement of the government, the U.S. Supreme Court agreed to take up the question of whether a federal law shields vaccine manufacturers from all liability for alleged vaccine design defects

Pharma Outside the Fray As Obama Re-Evaluates Bush’s Pre-emption Policy

The good news for drug firms about President Obama's memo curtailing federal pre-emption state laws: it won't have any real impact on industry. The bad news: it won't matter because pre-emption in the Rx arena was already dealt a body blow in the Supreme Court's recent ruling in Wyeth v. Levine

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS051019

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel